COMMUNIQUÉS West-GlobeNewswire

Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019
07/01/2019
- Two Additional Programs Advance to IND-Enabling Studies, Including First Gene Editing Program and a CNS Gene Therapy - - Homology’s New GMP Manufacturing Facility Preparing for Production at 500 Liter Scale - - Orphan [...]
Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference
07/01/2019
WALTHAM, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of [...]
William Demant Holding A/S: Managers' transactions
07/01/2019
Company announcement no 2019-01 7 January 2019 Report on transactions with William Demant Holding A/S shares by senior executives and closely related parties Notification on transactions with William Demant Holding A/S [...]
Syneos Health Names Paul Colvin, President, Clinical Solutions
07/01/2019
MORRISVILLE, N.C., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Paul Colvin as President, [...]
Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar® Digital Therapeutic
07/01/2019
COLUMBIA, Md., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Welldoc , a leading digital health company, announced today that it has secured a technology patent (based on U.S. Patent Application No. 15/923,010) from the United [...]
Sharp HealthCare, Cerner Expand Longstanding Relationship With Aim to Further Improve Patient Care
07/01/2019
SAN DIEGO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Sharp HealthCare, a leading health care provider in San Diego, has expanded its longstanding relationship with Cerner, a global leader in health care technology, with the [...]
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., a Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
07/01/2019
Joint Venture to Initially Focus on Development of Nacubactam, a Beta-Lactamase Inhibitor (BLI) for Severe Gram-Negative Enterobacteriaceae Infections EDMONTON, Alberta and Tokyo , Jan. 07, 2019 (GLOBE NEWSWIRE) -- [...]
AxoGen, Inc. Pre-Announces Financial and Operational Results
07/01/2019
Q4 Revenue of at least $23.4 million, a 38% YoY increase FY 2018 Revenue of at least $83.9 million, a 39% YoY increase Company reaffirms 2019 financial guidance and provides business update Appoints Chris Crisman to [...]
La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
07/01/2019
- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on [...]
Alphatec Announces 2018 Preliminary Revenue Results, 2019 Revenue Outlook, and Senior Leadership Changes
07/01/2019
CARLSBAD, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or “the Company”) (Nasdaq: ATEC) today announced preliminary revenue results for the fourth quarter and full year ended December 31, [...]
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
07/01/2019
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon ™ technologies to address significant unmet medical needs, [...]
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
07/01/2019
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (Nasdaq: [...]
Ceapro Announces 2019 Management Team and Grant of Stock Options and Restricted Share Units
07/01/2019
EDMONTON, Alberta, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients [...]
HealthEquity Announces Fiscal Year 2019 Sales Presentation at JP Morgan Healthcare Conference
07/01/2019
DRAPER, Utah, Jan. 07, 2019 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest independent health savings account (“HSA") custodian, today announced significant [...]
State of Georgia expands partnership with Sharecare to improve health of state employees, teachers and their families
07/01/2019
Walmart to contribute annual incentive dollars earned through Sharecare to help eligible State Health Benefit Plan members purchase prescription medications and vision products at its retail stores; Emory Healthcare and [...]
AxoGen Appoints Christopher Crisman as Vice President, U.S. Sales
07/01/2019
Brings nearly 30 years of medical device sales execution expertise having successfully built and led several large, productive sales organizations ALACHUA, Fla., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: [...]
CV Sciences, Inc. to Present at the 21st Annual ICR Conference
07/01/2019
LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) preeminent supplier and manufacturer of its industry-dominating brand of hemp CBD products, PlusCBD Oil™ , today announced that Joseph Dowling [...]
Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
07/01/2019
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for [...]
Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
07/01/2019
Novos to provide fully integrated commercial function for Evoke and non-dilutive financing for the commercialization of Gimoti, extending cash runway into 2020 Evoke will retain greater than 80% of product profits [...]

Pages